RABISIN

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

RABIES VIRUS GLYCOPROTEINS G52 RABIES VIRUS STRAIN

Inapatikana kutoka:

Merial Animal Health Limited

ATC kanuni:

QI07AA02

INN (Jina la Kimataifa):

RABIES VIRUS GLYCOPROTEINS G52 RABIES VIRUS STRAIN

Kipimo:

Per Cent

Dawa fomu:

Suspension for Injection

Dawa ya aina:

POM

Kundi la matibabu:

Bovine, Canine, Equine - Food, Feline, Mustelids, Ovine

Eneo la matibabu:

Rabies virus vaccine

Matibabu dalili:

Immunological - Inactivated vaccine

Idhini hali ya:

Authorised

Idhini ya tarehe:

2004-08-10

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabisin
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle, dogs, horses, cats, mustelids and sheep
.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of cattle, dogs, horses, cats, mustelids and sheep, to reduce mortality and clinical signs due to
rabies infection.
Immunity has been demonstrated 1 month after primary vaccination, and has been shown to persist up to the first
booster dose (1 year after primary vaccination).
In cats and dogs immunity has been shown to persist for up to 3 years following booster vaccination.
4.3 CONTRAINDICATIONS
Do not inject the vaccine subcutaneously in horses. Do not inject the vaccine intramuscularly in cats and dogs.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not vaccinate unhealthy animals
.
Each 1 ml dose of vaccine contains:
ACTIVE SUBSTANCE(S):
Rabies virus glycoproteins
1 IU
ADJUVANT(S):
Aluminium (as hydroxide)
1.7
mg
EXCIPIENT(S):
Excipient
q.s. 1
ml
For a full list of excipients, see section 6.1.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 04/09/2014_
_CRN 7016682_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
Where a dog or cat was vaccinated before 12 weeks of age, the primary vaccination scheme should be completed by an
injection given at 12 weeks of age or older.
Where horses, cattle or sheep were vaccinated before 4 months of age, the primary vaccination scheme should be
completed by an injection given at 4 months of age or older.
(II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON